LONDON, Dec 8 (APM) - Regulators in France, Germany, Belgium and Luxembourg are suspending the marketing approval of 25 generic drugs because of concerns over the quality of data from clinical trials conducted by India's GVK Biosciences, French regulator ANSM has said.
The quality of Indian pharmaceuticals has come under fire this year, with regulators in Europe and the U.S. citing problems ranging from data manipulation to sanitation and banning the import of certain products from several firms.
"This decision is taken out of precaution. No element at this stage has led to establish a true risk for human health or a lack of efficacy of these drugs," ANSM said on its website on Friday.
All of the drugs being suspended, several of which are made by Mylan and Abbott, have brand name equivalents that can be used instead, so patients will not have to interrupt their treatment, it added.
Thomson Reuters reported that ANSM and Germany's Federal Institute for Drugs and Medical Devices (BfArM) said they were investigating the drug approvals based on clinical trials which were meant to show that these generic drugs were equivalent to the original branded versions conducted by GVK Bio between 2008 and 2014.
ANSM said it had alerted European authorities after it inspected GVK Bio's site in Hyderabad, India, and found "anomalies" in the way electrocardiograms (ECG) were monitored during the bioequivalence studies.
It said the inspection raised serious concerns over whether the company's studies complied with good clinical practices.
GVK Bio's CEO Manni Kantipudi disputed the French watchdog's findings and said ECGs were not an important component of the drug efficacy, the news agency added.
ANSM concluded GVK Bio, which conducts clinical research for domestic and foreign drugmakers, manipulated the ECGs without taking into account the company's views, he said.
"We have agreed to redo the studies, I'm fine with that, but don't say that there was gross manipulation of the ECGs," Kantipudi told Reuters. He said the company had received board approval to spend $5.7-$6.5 million on new studies.
The European Medicines Agency (EMA) separately released a statement saying it would "issue a recommendation on whether the marketing authorisations of the concerned medicines should be maintained, varied, suspended or withdrawn across the EU". That recommendation is expected in January.
The German watchdog said it was investigating 176 approvals given to 28 drugmakers. It did not name the drugs or companies affected.
BfArM said it was ordering drugmakers whose approvals were found to have been based on data from GVK trials to stop distributing the concerned drugs until they could provide data from new studies.
France's ANSM said several drugmakers - it did not identify them - had already offered to carry out new studies which, if positive, could allow the drugs on the market again.
GVK Bio's Kantipudi said the company has started conducting new studies for five to six of its clients. About 35 of the company's 400 clients have been affected by the European regulator's move, he said.
He said the U.S. Food and Drug Administration inspected its Hyderabad plant in June, after the French regulator's audit, and was satisfied with the ECG-related data. No other regulator had contacted the company since then, he added.
rtr/nh/hlc
TRY APM Market Access AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to the latest stories
Our coverage includes:
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
REQUEST
an initial 10 day temporary access of APM Market Access.
